CHAPTER 2.2.4.
INFECTION WITH INFECTIOUS HYPODERMAL
AND HAEMATOPOIETIC NECROSIS

1. Scope

Infection with infectious hypodermal and haematopoietic necrosis virus means infection with the pathogenic agent Decapod pensthyamaparvovirus 1, of the Genus Pensthyamaparvovirus and Family Parvoviridae.

2. Disease information

2.1. Agent factors

2.1.1. Aetiological agent

IHHNV is the smallest of the known penaeid shrimp viruses. The virion is a 20–22 nm, non-enveloped icosahedron, with a density of 1.40 g ml⁻¹ in CsCl that contains linear single-stranded DNA with an estimated size of 3.9 kb (GenBank NC_002190), and has a capsid with four polypeptides of molecular weight 74, 47, 39, and 37.5 kD (Bonami et al., 1990; Nunan et al., 2000).

At least two distinct genotypes of IHHNV have been identified (Tang et al., 2003): Type 1 is from the Americas and South-East Asia (principally the Philippines) and Type 2 is from South-East Asia. These genotypes were shown to be infectious to Penaeus vannamei and P. monodon (Tang et al., 2003). IHHNV genotypes in Ecuador and Peru were found to be within a separate lineage of IHHNV type 2 genotypes circulating within these countries (Aranguen Caro et al., 2022). Two sequences homologous to part of the IHHNV genome are found embedded in the genome of penaeids. These were initially described as Type 3A from East Africa, India and Australia, and Type 3B from the western Indo-Pacific region including Madagascar, Mauritius and Tanzania (Tang & Lightner, 2006; Tang et al., 2007). Tissues containing the IHHNV-homologous sequences (also known as endogenous viral elements; Taengchaiyaphum et al., 2021) in the P. monodon genome are not infectious to susceptible host species (Lightner et al., 2009; Tang & Lightner, 2006; Tang et al., 2007).

2.1.2. Survival and stability in processed or stored samples

IHHNV is believed to be the most stable virus of the known penaeid shrimp viruses. Infected tissues remain infectious after repeated cycles of freeze–thawing and after storage in 50% glycerine (Lightner, 1996; Lightner et al., 1987; Lightner et al., 2009).

2.1.3. Survival and stability outside the host

No data.

For inactivation methods, see Section 2.4.5.

2.2. Host factors

2.2.1. Susceptible host species

Species that fulfil the criteria for listing as susceptible to infection with IHHNV according to Chapter 1.5 of Aquatic Animal Health Code (Aquatic Code) are: yellowleg shrimp (Penaeus californiensis), giant tiger prawn (Penaeus monodon), northern white shrimp (Penaeus setiferus), blue shrimp (Penaeus stylirostris), and white leg shrimp (Penaeus vannamei).
2.2.2. Species with incomplete evidence for susceptibility

Species for which there is incomplete evidence to fulfill the criteria for listing as susceptible to infection with IHHNV according to Chapter 1.5 of the Aquatic Code are: northern brown shrimp (*Penaeus aztecus*).

In addition, pathogen-specific positive polymerase chain reaction (PCR) results have been reported in the following organisms, but an active infection has not been demonstrated:

<table>
<thead>
<tr>
<th>Family</th>
<th>Scientific name</th>
<th>Common name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achiridae</td>
<td>Achirus mazatlanus</td>
<td>Mazatlan sole</td>
</tr>
<tr>
<td>Centropomidae</td>
<td>Centropomus medius</td>
<td>blackfin snook</td>
</tr>
<tr>
<td>Cichlidae</td>
<td>Oreochromis sp.</td>
<td>tilapias</td>
</tr>
<tr>
<td>Clupeidae</td>
<td>Lile stolifera</td>
<td>Pacific piquitinga</td>
</tr>
<tr>
<td>Gerreidae</td>
<td>Gerres cinereus</td>
<td>yellowfin mojarra</td>
</tr>
<tr>
<td>Palaemonidae</td>
<td>Macrobrachium rosenbergii</td>
<td>giant river prawn</td>
</tr>
<tr>
<td>Penaeidae</td>
<td>Penaeus duorarum</td>
<td>northern pink shrimp</td>
</tr>
<tr>
<td></td>
<td>Penaeus occidentalis</td>
<td>western white shrimp</td>
</tr>
<tr>
<td></td>
<td>Penaeus japonicus</td>
<td>kuruma prawn</td>
</tr>
<tr>
<td></td>
<td>Penaeus semisulcatus</td>
<td>green tiger prawn</td>
</tr>
<tr>
<td></td>
<td>Artemesia longinaris</td>
<td>Argentine stiletto shrimp</td>
</tr>
<tr>
<td>Portunidae</td>
<td>Callinectes arcuatus</td>
<td>Cuata swimcrab</td>
</tr>
<tr>
<td>Varunidae</td>
<td>Hemigrapsus penicillatus</td>
<td></td>
</tr>
</tbody>
</table>

2.2.3. Likelihood of infection by species, host life stage, population or sub-populations

IHHNV has been detected in all life stages (i.e. eggs, larvae, postlarvae [PL], juveniles and adults) of *P. vannamei*. Nauplii produced from infected broodstock have a high prevalence of infection with IHHNV (Motte *et al.*, 2003).

2.2.4. Distribution of the pathogen in the host

IHHNV targets gills, haematopoietic nodules and haemocytes, ventral nerve cord and ganglia, antennal gland tubule epithelial cells, lymphoid organ, parenchymal cells, connective tissue cells and ovaries (Chayaburakul, 2005; Lightner, 1996; Lightner & Redman, 1998).

2.2.5. Aquatic animal reservoirs of infection

Some members of *P. stylirostris* and *P. vannamei* populations that survive IHHNV infection may carry the virus subclinically and infect their progeny or other populations by vertical and horizontal transmission (Bell & Lightner, 1984; Lightner, 1996; Motte *et al.*, 2003).

2.2.6. Vectors

IHHNV has been detected in many crustacean and non-crustacean species however their capacity to transmit virus is unknown.

2.3. Disease pattern

2.3.1. Mortality, morbidity and prevalence

The effects of infection with IHHNV varies among shrimp species and populations, where infections can be either acute or chronic. For example, in unselected populations of *P. stylirostris*, infection with IHHNV results in acute, usually catastrophic, disease with mortalities approaching 100%. Vertically infected larvae and early PL do not become diseased, but in approximately 35-day-old or older juveniles, gross signs of the disease may be observed, followed by mass mortalities. In horizontally infected juveniles, the incubation period and severity of the disease is somewhat size- or age-dependent, with young juveniles always being the most severely affected. Infected adults seldom show signs of the disease or mortalities (Bell & Lightner, 1984; 1987; Lightner, 1996; Lightner *et al.*, 1983).
In contrast, in populations of *P. vannamei*, some selected lines of *P. stylirostris*, and some populations of *P. monodon*, infection with IHHNV results in a more subtle, chronic disease, runt-deformity syndrome (RDS), in which high mortalities are unusual, but where growth suppression and cuticular deformities are common (Kalagayan et al., 1991; Sellars et al., 2019). The severity and prevalence of RDS in infected populations of juvenile or older *P. vannamei* may be related to infection during the larval or early postlarval stages.

There was no mortality or clinical signs of disease in *P. vannamei*, *P. monodon* or *P. stylirostris* when experimentally challenged with IHHNV genotypes from Ecuador and Peru. The IHHNV genotypes were found to be within a separate lineage of IHHNV type 2 genotypes circulating within these countries (Aranguen Caro et al., 2022).

In the past, stocks of *P. stylirostris*, juveniles, and adults showed persistently high mortality rates due to infection with IHHNV. However, selected lines of *P. stylirostris* do not show mortality and appear to be tolerant to this virus.

In regions where the virus is enzootic in wild stocks, the prevalence of IHHNV has been found in various surveys to range from 0 to 100%. Some reported mean values for IHHNV prevalence in wild stocks are: 26% and 46% in *P. stylirostris* in the lower and upper Gulf of California, respectively (Pantoja et al., 1999); 100% and 57%, respectively, in adult female and adult male *P. stylirostris* from the mid-region of the Gulf of California (Morales-Covarrubias et al., 1999); 28% in wild *P. vannamei* collected from the Pacific coast of Panama (Nunan et al., 2001); from 51 to 63% in *P. vannamei* collected from the Pacific coasts of Ecuador, Colombia and Panama (Motte et al., 2003), and from 6 to 63% in *P. vannamei* broodstock and 49.5% in post-larvae from Mexico (Fernando et al., 2016). In farms where IHHNV is present, its prevalence can range from very low to 100%, but high prevalence is typical (Aly et al., 2021; Chayaburakul et al., 2004; Lightner, 1996; Lightner et al., 1983).

### 2.3.2. Clinical signs, including behavioural changes

Animals with this disease may show one or more of these signs, but the pathogen may still be present in the absence of any signs. Clinical signs are non-specific, but juvenile *P. stylirostris* with acute infection with IHHNV show a marked reduction in food consumption, followed by changes in behaviour and appearance. Shrimp of this species infected with IHHNV have been observed to rise slowly in culture tanks to the water surface, where they become motionless and then roll-over and slowly sink (ventral side up) to the tank bottom. Shrimp exhibiting this behaviour may repeat the process for several hours until they become too weak to continue, or until they are attacked and cannibalised by their healthier siblings.

Certain cuticular deformities, specifically a deformed rostrum bent to the left or right, which may be presented by *P. vannamei* and *P. stylirostris* with RDS, are indicative of infection with IHHNV. However, this clinical sign is not always apparent in shrimp populations chronically infected with IHHNV.

In acute disease, *P. stylirostris* may present behavioural changes but with RDS, no consistent behavioural changes have been reported for affected shrimp.

Infection with IHHNV interferes with normal egg, larval, and postlarval development. When broodstock are used from wild or farmed stocks where the disease is enzootic, hatching success of eggs may be reduced, and survival and culture performance of the larval and postlarval stages lowered (Motte et al., 2003).

### 2.3.3. Gross pathology

Juvenile shrimp with RDS may display a bent (45° to 90° bend to left or right) or otherwise deformed rostrum, a deformed sixth abdominal segment, wrinkled antennal flagella, cuticular roughness, ‘bubble-heads’, and other cuticular deformities. Populations of juvenile shrimp with RDS display disparate growth with a wide distribution of sizes and many smaller than expected (‘runted’) shrimp. The coefficient of variation (CV = the standard deviation divided by the mean of different size groups within a population) for populations with RDS is typically greater than 30% and may approach 90%, while populations of juvenile *P. vannamei* and *P. stylirostris* free from infection with IHHNV (and thus RDS-free) usually show CVs of 10–30% (Lightner, 1996; Primavera & Quinitio, 2000).
2.3.4. Modes of transmission and life cycle

Transmission of IHHNV can be by horizontal or vertical. Horizontal transmission has been demonstrated by cannibalism or by contaminated water (Lightner, 1996; Lightner et al., 1983), and vertical transmission via infected eggs (Motte et al., 2003).

2.3.5. Environmental factors

The replication rate of IHHNV at high water temperatures was significantly reduced in a study in which viral replication was compared in P. vannamei experimentally infected and held at 24°C and 32°C. After a suitable incubation period, shrimp held at 32°C had approximately $10^2$ times lower viral load than shrimp held at 24°C (Montgomery-Brock et al., 2007).

2.3.6. Geographical distribution

Infection with IHHNV has been reported from cultured shrimp in most of the major shrimp-culturing regions of the world including Asia, Oceania, North and South America and the Middle East.

IHHNV homologous sequences have been found within the genome of P. monodon from East Africa, Australia, and the western Indo-Pacific region (Tang & Lightner, 2006; Tang et al., 2007). These sequences do not represent viral DNA (refer Section 2.1.1 Aetiological agent).

See WOAH WAHIS (https://wahis.woah.org/#/home) for recent information on distribution at the country level.

2.4. Biosecurity and disease control strategies

2.4.1. Vaccination

None available.

2.4.2. Chemotherapy including blocking agents

No scientifically confirmed reports.

2.4.3. Immunostimulation

No scientifically confirmed reports.

2.4.4. Breeding resistant strains

Selected stocks of P. stylirostris that are resistant to infection with IHHNV have been developed and these have had some successful application in shrimp farms (Lightner, 1996). However, lines of P. stylirostris bred for resistance to infection with IHHNV (Tang et al., 2000) do not have increased resistance to other diseases, such as white spot syndrome virus (WSSV), so their use has been limited. In some stocks a genetic basis for IHHNV susceptibility in P. vannamei has been reported (Alcivar-Warren et al., 1997).

2.4.5. Inactivation methods

IHHNV is a stable shrimp virus; infected tissues remain infectious after repeated cycles of freeze-thawing and after storage in 50% glycerine (Lightner, 1996; Lightner et al., 2009).

2.4.6. Disinfection of eggs and larvae

IHHNV is transmitted vertically by the transovarian route (Motte et al., 2003). Disinfection of eggs and larvae is good management practice (Chen et al., 1992) that may reduce IHHNV contamination of spawned eggs and larvae but is not effective for preventing transovarian transmission of IHHNV (Motte et al., 2003).
2.4.7. General husbandry

Some husbandry practices have been successful in preventing the spread of IHHNV. Among these has been the application of PCR pre-screening of wild or pond-reared broodstock or their spawned eggs/nauplii and discarding those that test positive for the virus (Motte et al., 2003), as well as the development of specific pathogen-free (SPF) shrimp stocks of *P. vannamei* and *P. stylirostris* (Lightner, 2005). The latter has proven to be the most successful husbandry practice for the prevention and control of infection with IHHNV (Lightner, 2005).

3. Specimen selection, sample collection, transportation and handling

This section draws on information in Sections 2.2, 2.3 and 2.4 to identify populations, individuals and samples that are most likely to be infected.

3.1. Selection of populations and individual specimens

Specimens suitable for testing for infection with IHHNV include PL, juveniles and adults. While IHHNV may infect all life stages, virus load may be below detection limits in spawned eggs and larval stages, so these life stages are not suitable for surveillance to demonstrate freedom from infection with IHHNV.

3.2. Selection of organs or tissues

IHHNV infects tissues of ectodermal and mesodermal origin. The principal target tissues for IHHNV include connective tissue cells, the gills, haematopoietic nodules and haemocytes, ventral nerve cord and ganglia, antennal gland tubule epithelial cells, and lymphoid organ parenchymal cells (Lightner, 1996; Lightner & Redman, 1998). Hence, whole shrimp (e.g. larvae or PL) or tissue samples containing the aforementioned target tissues are suitable for most tests using molecular methods.

3.3. Samples or tissues not suitable for pathogen detection

Enteric tissues (e.g. the hepatopancreas, the midgut or its caeca) are inappropriate samples for detection of IHHNV (Lightner, 1996; Lightner & Redman, 1998). Shrimp eyes contain PCR inhibitors and their use should be avoided.

3.4. Non-lethal sampling

Haemolymph or excised pleopods may be collected and used for testing when non-lethal testing of valuable broodstock is necessary (Lightner, 1996; Lightner & Redman, 1998).

If non-lethal tissue sample types differ from recommended tissues (see Section 3.2.), or from the tissue samples used in validation studies, the effect on diagnostic performance should be considered.

3.5. Preservation of samples for submission

For routine histology or molecular assays, and guidance on preservation of samples for the intended test method see Chapter 2.2.0 *General information* (diseases of crustaceans).

3.5.1. Samples for bioassay

The results of bioassay depend strongly on the quality of samples (time since collection and time in storage). Fresh specimens should be kept on ice and preferably sent to the laboratory within 24 hours of collection. To avoid degradation of samples, use alternative storage methods only after consultation with the receiving laboratory.

3.5.2. Preservation of samples for molecular detection

Standard sample collection, preservation and processing methods for molecular techniques can be found in Section B.5.5. of Chapter 2.2.0 *General information* (diseases of crustaceans).
3.5.3. Samples for histopathology, immunohistochemistry or in-situ hybridisation

Standard sample collection, preservation and processing methods for histological techniques can be found in Section B.5.3 of Chapter 2.2.0 General information (diseases of crustaceans).

3.5.4. Samples for other tests

Not relevant.

3.6. Pooling of samples

Pooling of samples from more than one individual animal for a given purpose should only be recommended where robust supporting data on diagnostic sensitivity and diagnostic specificity have been evaluated and found to be suitable. The effect of pooling on diagnostic sensitivity has not been thoroughly evaluated, therefore, larger shrimp should be processed and tested individually. Small life stages such as PL can be pooled to obtain the minimum amount of material for molecular detection.

4. Diagnostic methods

The methods currently available for pathogen detection that can be used in i) surveillance of apparently healthy animals, ii) presumptive diagnosis in clinically affected animals and iii) confirmatory diagnostic purposes are listed in Table 4.1. by animal life stage.

Ratings for purposes of use. For each recommended assay a qualitative rating for the purpose of use is provided. The ratings are determined based on multiple performance and operational factors relevant to application of an assay for a defined purpose. These factors include appropriate diagnostic performance characteristics, level of assay validation, availability cost, timeliness, and sample throughput and operability. For a specific purpose of use, assays are rated as:

+++ = Methods are most suitable with desirable performance and operational characteristics.
++ = Methods are suitable with acceptable performance and operational characteristics under most circumstances.
+ = Methods are suitable, but performance or operational characteristics may limit application under some circumstances.
Shaded boxes = Not appropriate for this purpose.

Validation stage. The validation stage corresponds to the assay development and validation pathway in chapter 1.1.2. The validation stage is specific to each purpose of use. Where available, information on the diagnostic performance of recommended assays is provided in Section 6.3.

WOAH Reference Laboratories welcome feedback on diagnostic performance of recommended assays, in particular PCR methods. Of particular interest are any factors affecting expected assay sensitivity (e.g. tissue components inhibiting amplification) or expected specificity (e.g. failure to detect particular genotypes, detection of homologous sequences within the host genome). These issues should be communicated to the WOAH Reference Laboratories so that advice can be provided to diagnostic laboratories and the standards amended if necessary.
Table 4.1. WOAH recommended diagnostic methods and their level of validation for surveillance of apparently healthy animals and investigation of clinically affected animals

<table>
<thead>
<tr>
<th>Method</th>
<th>A. Surveillance of apparently healthy animals</th>
<th>B. Presumptive diagnosis of clinically affected animals</th>
<th>C. Confirmatory diagnosis(^1) of a suspect result from surveillance or presumptive diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Early life stages(^2)</td>
<td>Juveniles(^2)</td>
<td>Adults</td>
</tr>
<tr>
<td>Wet mounts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histopathology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell culture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Real-time PCR</td>
<td>+++</td>
<td>+++</td>
<td>1</td>
</tr>
<tr>
<td>Conventional PCR</td>
<td>++</td>
<td>++</td>
<td>1</td>
</tr>
<tr>
<td>Conventional PCR followed by amplicon sequencing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In-situ hybridisation</td>
<td>+</td>
<td>+</td>
<td>1</td>
</tr>
<tr>
<td>Bioassay</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>LAMP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ab-ELISA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ag-ELISA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other antigen detection methods</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other methods</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LV = level of validation, refers to the stage of validation in the WOAH Pathway (chapter 1.1.2); NA = not available; PCR = polymerase chain reaction; LAMP = loop-mediated isothermal amplification; Ab- or Ag-ELISA = antibody or antigen enzyme-linked immunosorbent assay, respectively.

\(^1\)For confirmatory diagnoses, methods need to be carried out in combination (see Section 6). \(^2\)Susceptibility of early and juvenile life stages is described in Section 2.2.3.

Shading indicates the test is inappropriate or should not be used for this purpose.
4.1. **Wet mounts**

No reliable methods have been developed for direct microscopic pathology.

4.2. **Histopathology and cytopathology**

Presumptive acute infections in *P. stylirostris* can be readily diagnosed using routine haematoxylin and eosin (H&E) stained sections whereas chronic infection are much more difficult to diagnose using these staining methods. For diagnosis of chronic infections and confirmation of acute infections however, the use of molecular methods is required for IHHNV detection (e.g. by PCR or application of IHHNV-specific DNA probes to dot-blot hybridisation tests or *in-situ* hybridisation [ISH] of histological sections).

Histological demonstration of prominent intranuclear, Cowdry type A inclusion bodies, provides a provisional diagnosis of infection with IHHNV. These characteristic IHHNV inclusion bodies are eosinophilic and often haloed (with H&E stains of tissues preserved with fixatives that contain acetic acid, such as Davidson's AFA and Bouin's solution) (Bell & Lightner, 1988; Lightner, 1996). Intranuclear inclusion bodies within chromatin-marginated, hypertrophied nuclei of cells in tissues of ectodermal (epidermis, hypodermal epithelium of fore- and hindgut, nerve cord and nerve ganglia) and mesodermal origin (haematopoietic organs, antennal gland, gonads, lymphoid organ, and connective tissue). Intranuclear inclusion bodies caused by infection with IHHNV may be easily confused with developing intranuclear inclusion bodies caused by WSSV infection. ISH assay (see Section 4.6 *In-situ* hybridisation) of such sections with a DNA probe specific to IHHNV provides a definitive diagnosis of infection with IHHNV (Lightner, 1996a; 2011; Lightner & Redman, 1998a).

The use of Davidson's fixative (containing 33% ethyl alcohol [95%), 22% formalin [approximately 37% formaldehyde], 11.5% glacial acetic acid and 33.5% distilled or tap water) is highly recommended for all routine histological studies of shrimp (Bell & Lightner, 1988; Lightner, 1996a). To obtain the best results, dead shrimp should not be used. Only live, moribund, or compromised shrimp should be selected for fixation and histological examination. Selected shrimp are killed by injection of fixative directly into the hepatopancreas; the cuticle over the cephalothorax and abdomen just lateral to the dorsal midline is opened with fine-pointed surgical scissors to enhance fixative penetration (the abdomen may be removed and discarded), the whole shrimp (or cephalothorax) is immersed in fixative for 24 to 48 hours, and then transferred to 70% ethyl alcohol for storage. After transfer to 70% ethyl alcohol, fixed specimens may be transported by wrapping in cloth or a paper towel saturated with 70% ethyl alcohol and packed in leak-proof plastic bags.

4.3. **Cell culture for isolation**

IHHNV has not been grown in *vitro*. No crustacean cell lines exist.

4.4. **Nucleic acid amplification**

PCR assays should always be run with the controls specified in Section 5.5 Use of molecular and antibody-based techniques for confirmatory testing and diagnosis of Chapter 2.2.0 General information (diseases of crustaceans). Each sample should be tested in duplicate.

**Extraction of nucleic acids**

Different kits and procedures can be used for nucleic acid extraction. The quality and concentration of the extracted nucleic acid is important and can be checked using a suitable method as appropriate to the circumstances.

There are multiple variants of IHHNV, some of which are not detected by some available methods. Two primer sets, 392F/R and 389F/R, are the most suitable for detecting all the known genetic variants of IHHNV (Tang et al., 2000; 2007). However, these tests also detect non-infectious endogenous viral elements (EVE) within the *P. monodon* genome (previously known as types 3A and 3B), which are inserted into the genome of certain stocks of *P. monodon* from the western Indo-Pacific, East Africa, Australia and India (Saksmerprone et al., 2011; Taengchayaphum et al., 2022; Tang & Lightner, 2006; Tang et al., 2007). As these PCR methods may result in positive test results in uninfected *P. monodon*, positive results should be confirmed by a method that detects IHHNV but not the IHHNV-related EVEs.
PCR primers have been developed that can detect the IHHNV sequence but do not amplify IHHNV-related EVEs present in the *P. monodon* stocks from Africa, Australia (Tang et al., 2007), or Thailand (Saksmerprome et al., 2011). Primer set 309F/R amplifies only a genomic segment of IHHNV types 1 and 2, but not the non-infectious EVEs within the *P. monodon* genome (Tang & Lightner, 2006; Tang et al., 2007). Hence, confirmation of unexpected positive or negative PCR results for IHHNV with a second primer set, or use of another diagnostic method (i.e. histology, bioassay, ISH) is highly recommended.

### 4.4.1. Real-time PCR

Real-time PCR methods have been developed for the detection of IHHNV (Dhar et al., 2001; Tang & Lightner, 2001). A SYBR Green real-time PCR targeting a segment of the IHHNV genome considered less susceptible to endogenisation was developed (Encinas-Garcia et al., 2015). A TaqMan real-time assay developed to differentiate EVEs from infectious form of IHHNV in *P. monodon* has been reported (Cowley et al., 2018); however, analysis of a *P. monodon* whole genome sequence has identified 100% primer and probe sequence matches to EVEs (Taengchaiyaphum et al., 2022). The real-time PCR method described in Table 4.4.1.1 generally follows the method used in Tang & Lightner (2001).

**Table 4.4.1.1. Primers and probes for real-time PCR detection of IHHNV**

<table>
<thead>
<tr>
<th>Pathogen/ target gene</th>
<th>Primer/probe (5’–3’)</th>
<th>Concentration</th>
<th>Cycling parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Method 1</strong> Tang &amp; Lightner, 2001; GenBank Accession No.: AF218266</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*NOTE – this method will amplify EVEs within the genome of *P. monodon*. Positive results in this species must be confirmed by a method that does not react with IHHNV EVEs.*

### 4.4.2. Conventional PCR

Several one-step PCR methods (Krabsetsve et al., 2004; Nunan at al., 2000; Shike et al., 2000; Tang et al., 2000; 2007), and a number of commercial PCR kits are available for IHHNV detection. Nested methods are also available. In addition to IHHNV, some of these methods will amplify EVEs in *P. monodon*. Positive results in *P. monodon* should be followed up with other methods that will not react with EVEs.

**Table 4.4.2.1. Recommended primer sets for conventional PCR detection of IHHNV**

<table>
<thead>
<tr>
<th>Pathogen/ target gene</th>
<th>Primer (5’–3’)</th>
<th>Concentration</th>
<th>Cycling parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Method 1</strong> Tang et al., 2007; GenBank Accession No.: AF218266; amplicon size 389 bp</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Chapter 2.2.4. – Infection with infectious hypodermal and haematopoietic necrosis virus

<table>
<thead>
<tr>
<th>Pathogen/target gene</th>
<th>Primer (5’–3’)</th>
<th>Concentration</th>
<th>Cycling parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method 2* Nunan et al., 2000; GenBank Accession No.: AF218266; amplicon size 356 bp</td>
<td>IHHNV and IHHNV-related EVEs Between the non-structural and capsid protein-coding regions</td>
<td>Fwd 77012F: ATC-GGT-GCA-CTA-CTC-GGA Rev 77353R: TCG-TAC-TGG-CTG-TTC-ATC</td>
<td>1000 nM</td>
</tr>
</tbody>
</table>

*NOTE – these methods will amplify EVEs within the genome of *P. monodon*. Positive results in this species must be confirmed by a method that does not react with IHHNV EVEs.

4.4.3. Other nucleic acid amplification methods

Loop-mediated isothermal amplification (LAMP) assays and a real-time isothermal recombinase polymerase amplification (RPA) assay to detect IHHNV have been published (Arunrut et al., 2011; Sun et al., 2006; Xia et al., 2015), however, they are currently not recommended as they are not sufficiently validated.

4.5. Amplicon sequencing

The size of the PCR amplicon should be verified, for example by agarose gel electrophoresis. Both DNA strands must be sequenced and analysed in comparison with reference sequences.

4.6. *In-situ* hybridisation

Direct detection methods using DNA probes specific for IHHNV are available in dot-blot and ISH formats. The ISH method uses a DIG-labelled DNA probe for IHHNV and generally follows the methods outlined in Mari et al. (1993) and Lightner (1996).

Gene probe and PCR methods provide greater diagnostic specificity and sensitivity than traditional techniques that employ classic histological approaches. Furthermore, these methods have the added advantage of being applicable to non-lethal testing of valuable broodstock shrimp. A haemolymph sample may be taken with a tuberculin syringe, or an appendage (a pleopod for example) may be biopsied (Bell et al., 1990), and used as the sample for a dot-blot hybridisation test.

4.7. Immunohistochemistry

Not relevant.

4.8. Bioassay

If SPF shrimp are available, the following bioassay method is based on Tang et al. (2000), is suitable for IHHNV diagnosis.
i) For bioassay, feed the minced shrimp tissue suspected of being infected with IHHNV to the indicator shrimp species (e.g. SPF P. vannamei and P. stylirostris at the PLs or juvenile stage) at 10% of their body weight twice daily for 1 day.

ii) For the following, the indicator shrimp were maintained on a pelletised ration.

iii) Examine moribund shrimp grossly or by using the methods described above. There may be no apparent mortality during the experimental period.

iv) If at 30 days after feeding there are still no moribund shrimp and all molecular test results are negative, then it is safe to conclude that the bioassay results are negative.

Known IHHNV positive and negative control groups should be included in the bioassay.

4.9. Antibody- or antigen-based detection methods

None has been successfully developed.

4.10. Other methods

Not available.

5. Test(s) recommended for surveillance to demonstrate freedom in apparently healthy populations

Conventional PCR and/or real-time PCR are the recommended test for surveillance to demonstrate freedom from infection with IHHNV in apparently healthy populations as described in Sections 4.4.1 and 4.4.2.

6. Corroborative diagnostic criteria

This section only addresses the diagnostic test results for detection of infection in the absence (Section 6.1.) or in the presence of clinical signs (Section 6.2.) but does not evaluate whether the infectious agent is the cause of the clinical event.

The case definitions for a suspect and confirmed case have been developed to support decision making related to trade and confirmation of disease status at the country, zone or compartment level. Case definitions for disease confirmation in endemically affected areas may be less stringent. If a Competent Authority does not have the capability to undertake the necessary diagnostic tests it should seek advice from the appropriate WOAH Reference Laboratory, and if necessary, refer samples to that laboratory for confirmatory testing of samples from the index case in a country, zone or compartment considered free.

6.1. Apparently healthy animals or animals of unknown health status

Apparantly healthy populations may fall under suspicion, and therefore be sampled, if there is an epidemiological link(s) to an infected population. Hydrographical proximity to, or movement of animals or animal products or equipment, etc., from a known infected population equate to an epidemiological link. Alternatively, healthy populations are sampled in surveys to demonstrate disease freedom.

6.1.1. Definition of suspect case in apparently healthy animals

The presence of infection with IHHNV shall be suspected if at least one of the following criteria is met:

i) Positive result by IHHNV PCR

ii) Positive result by conventional PCR

---

1 For example transboundary commodities.
6.1.2. Definition of confirmed case in apparently healthy animals

The presence of infection with IHHNV is considered to be confirmed if the following criterion is met:

i) Positive result by real-time PCR and a positive result by conventional PCR followed by amplicon sequencing

6.2 Clinically affected animals

Clinical signs are not pathognomonic for a single disease; however they may narrow the range of possible diagnoses.

6.2.1. Definition of suspect case in clinically affected animals

The presence of infection with IHHNV shall be suspected if at least one of the following criteria is met:

i) Gross pathology or clinical signs associated with the disease as described in this chapter, with or without elevated mortality
ii) Histopathology consistent with IHHNV infection
iii) Positive result by conventional PCR
iv) Positive result by real-time PCR
v) Positive result by in-situ hybridisation
vi) Positive result by bioassay

6.2.2. Definition of confirmed case in clinically affected animals

The presence of infection with IHHNV is considered to be confirmed if at least one of the following criteria is met:

i) Positive result by real-time PCR and a positive result by conventional PCR followed by amplicon sequencing
ii) A positive result by in-situ hybridisation and a positive result by real-time PCR
iii) A positive result by in-situ hybridisation and a positive result by conventional PCR followed by amplicon sequencing

6.3. Diagnostic sensitivity and specificity for diagnostic tests [under study]

The diagnostic performance of tests recommended for surveillance or diagnosis of infection with IHHNV is provided in Tables 6.3.1. and 6.3.2 (no data are currently available for either). This information can be used for the design of surveys for infection with IHHNV, however, it should be noted that diagnostic performance is specific to the circumstances of each diagnostic accuracy study (including the test purpose, source population, tissue sample types and host species) and diagnostic performance may vary under different conditions. Data are only presented where tests are validated to at least level 2 of the validation pathway described in Chapter 1.1.2 and the information is available within published diagnostic accuracy studies.

6.3.1. For presumptive diagnosis of clinically affected animals

<table>
<thead>
<tr>
<th>Test type</th>
<th>Test purpose</th>
<th>Source populations</th>
<th>Tissue or sample types</th>
<th>Species</th>
<th>DSe (n)</th>
<th>DSp (n)</th>
<th>Reference test</th>
<th>Citation</th>
</tr>
</thead>
</table>

DSe = diagnostic sensitivity, DSp = diagnostic specificity, n = number of samples used in the study,
PCR: = polymerase chain reaction.
6.3.2. For surveillance of apparently healthy animals

<table>
<thead>
<tr>
<th>Test type</th>
<th>Test purpose</th>
<th>Source populations</th>
<th>Tissue or sample types</th>
<th>Species</th>
<th>DSe (n)</th>
<th>DSp (n)</th>
<th>Reference test</th>
<th>Citation</th>
</tr>
</thead>
</table>

DSe = diagnostic sensitivity, DSp = diagnostic specificity, n = number of samples used in the study.

7. References


Chapter 2.2.4. – Infection with infectious hypodermal and haematopoietic necrosis virus


**Chapter 2.2.4. – Infection with infectious hypodermal and haematopoietic necrosis virus**


**NB:** There are WOAH Reference Laboratories for infection with infectious hypodermal and haematopoietic necrosis virus (please consult the WOAH web site for the most up-to-date list: [http://www.woah.org/en/scientific-expertise/reference-laboratories/list-of-laboratories/](http://www.woah.org/en/scientific-expertise/reference-laboratories/list-of-laboratories/)).

Please contact the WOAH Reference Laboratories for any further information on infection with infectious hypodermal and haematopoietic necrosis virus.

**NB:** First adopted in 1995 as infectious hypodermal and haematopoietic necrosis. Most recent updates adopted in 2023.